2016 American Transplant Congress
The Impact of Ritonavir-Boosted Protease Inhibitors and Non-Depleting Antibody Induction on Outcomes in HIV-Infected Kidney Transplant Recipients.
Mount Sinai Hospital, New York.
Background: One-year rejection rates in HIV-infected kidney transplant recipients range from 15-40%, compared to overall rejection rates of 10% in HIV-negative patients. Protocols for immunosuppression…2016 American Transplant Congress
Phenotype and Outcome of Antibody-Mediated Rejection Due to Pre-Existing and De Novo DSA in Kidney Recipients.
Antibody-mediated rejection (ABMR) presents with either pre-existing or de novo DSA. The aim of the study was to compare the two ABMR phenotypes and their…2016 American Transplant Congress
Rapid Detection of Urinary CXCL9 as a Diagnostic and Prognostic Tool for Managing Acute Cellular Rejection (ACR) in Kidney Transplantation.
Urinary (u) CXCL9 protein expression can noninvasively diagnose ACR and serial measurements during CNI withdrawal indicate that elevations in uCXCL9 detect subclinical rejection. How elevated…2016 American Transplant Congress
Outcomes with Steroids Alone for Biopsy-Proven Pancreas Transplant Rejection.
There is little published data on the response of pancreas rejection to steroids alone. We reviewed 42 pancreas transplant recipients between 01/1997 and 12/2013 at…2016 American Transplant Congress
Continuous Antithymocyte Globulin (rATG) for Treatment of Renal Allograft Rejection: Preliminary Analysis of a Prospective, Randomized Trial.
Houston Methodist Hospital, Houston, TX.
Intravenous (IV) rATG for acute rejection (AR) is primarily given on an inpatient basis due to its daily administration, IV access requirement, and monitoring. The…2016 American Transplant Congress
CD45RO+/CD62L- Effector Memory T Cells Mediate Depletion Resistant Allograft Rejection in Intestinal Transplant Recipients.
MedStar Georgetown Transplant Institute, Washington DC.
A. A high risk of acute cellular rejection (ACR) is one of the key factors limiting intestinal transplantation (ITx). An extremely poor prognosis is related…2016 American Transplant Congress
Frequency and Utility of Donor-Specific Antibody Testing in Simultaneous Liver Kidney Transplant.
Introduction: The risk of antibody mediated rejection (AMR) in simultaneous liver kidney (SLK) recipients is thought to be lower than in kidney alone patients due…2016 American Transplant Congress
Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection.
Columbia University Medical Center, NYC.
Intro: CAAMR is an increasingly recognized cause of renal allograft failure with limited treatment options. Many patients with CAAMR have engagement of both T and…2016 American Transplant Congress
Influence of Country-Associated Geographical Variables in the Ouctomes of Kidney Transplantation in Patients with HIV-Infection.
Objective: To evaluate effects of geographical factors on demography, clinical management and evolution of two cohorts of HIV-infected KT recipients.Methods: Observational, retrospective cohort study including…2016 American Transplant Congress
Factors Mediating Kidney Rejection in Patients of Simultaneous Liver-Kidney Transplants.
BACKGROUND & AIM: Kidney grafts in simultaneous liver-kidney (SLK) recipients are considered to be immunologically protected due to hepatic tolerance, although recent studies have alternatively…
- « Previous Page
- 1
- …
- 128
- 129
- 130
- 131
- 132
- …
- 172
- Next Page »